PMDA Regulatory Writing Services: Navigate Japan’s Regulatory Requirements with Confidence

An Academy Guide

Interesting topics

PMDA Regulatory Writing Services: Navigate Japan’s Regulatory Requirements with Confidence

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) plays a crucial role in the global regulatory landscape, regulating the safety, efficacy and quality of pharmaceuticals and medical devices. Companies planning to enter the Japanese market must familiarize themselves with the strict requirements imposed by PMDA. Thus, PMDA-compliant regulatory writing expertise is needed for meeting PMDA’s evidentiary requirements and filing expectations.

The Importance of PMDA Regulatory Writing

The PMDA performs a similar role as FDA in the United States and EMA in Europe, however, specific to Japan, the regulatory environment calls for the documentation to be both scientifically rigorous and culturally relevant [1]

Why Effective PMDA Regulatory Writing is Critical

The PMDA’s functions and processes are like other global regulatory agencies, such as the FDA in the United States or EMA in Europe, however the specifics of Japan’s regulatory framework also impact the regulatory writing that the PMDA expects to receive.

eCTD v4.0 compliance: The PMDA requires that documents submitted to them must be in the Electronic Common Technical Document (eCTD) format and the use of eCTD v4.0 will be mandatory by 2026.
CDISC compliance: Clinical study data will need to be submitted that comply with CDISC standards to facilitate the PMDA’s review.
Japanese language compliance: All documents submitted to the PMDA will need to be provided in the Japanese language and the translation and localization applied needs to be precise [2]

Our PMDA Regulatory Writing Services

At [Your Company Name], we provide comprehensive regulatory writing services that support all aspects of PMDA requirements:

Regulatory Dossier Preparation: Preparing complete and comprehensive dossiers to PMDA requirements, with the right information included and in the right order.
Clinical Study Reports (CSRs): Writing robust CSRs that meet PMDA CR requirements, and that also include all required data and analysis.
Quality Management System (QMS) Documentation: Support with the preparation of QMS documentation to PMDA requirements including ISO 13485 standards
Translation and Localization: Reliable translation services, including all documents translated to Japanese, and culturally appropriate documents.
Consultation Support: Support guiding clients through the PMDA consultation processes including strategy development, document preparation [3].

Why Us?

We Have Depth of Experience with Japanese Regulations: Our staff is experienced with the specifications of PMDA and will keep you compliant every step along the way.

We Understand Cultural Considerations: We know the “for” in Japan and will build your system considering these concerns.
We Provide Efficiency and Accuracy: We will provide timeliness and high-quality documents so you can keep the approval process smooth instead of going back to fix issues.
Full Cycle Service: We will provide the full cycle of regulatory writing, from the initial conversation to jumping over the last hurdle [4].

Conclusions

Navigating the PMDA’s regulatory landscape can be complicated; however, with the right support; it is manageable. We provide specialized regulatory writing services that will meet PMDA’s stringent criteria to provide your products a smooth and efficient process towards approval. Let the experts help you navigate your best path to market entry in Japan.

Reference

2015. Technical Conformance Guide on Electronic Study Data Submissions. Accessed on December 9, 2022. https://www.pmda.go.jp/files/000206449.pdf
2014. Basic Principles on Electronic Submission of Study Data for New Drug Applications. Accessed on December 9, 2022. https://www.pmda.go.jp/files/000160019.pdf.
The pilot projects to confirm the feasibility of the submitted electronic data utilization system. Accessed on December 9, 2022.https://www.pmda.go.jp/english/review-services/reviews/0007.html.
2014. Basic Principles on Electronic Submission of Study Data for New Drug Applications. Accessed on December 9, 2022.https://www.pmda.go.jp/files/000160019.pdf.